Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases

doi:10.1186/1546-0096-7-9

Pediatric Rheumatology

Volume 7

Viewing options:

Abstract
Full text
PDF (425KB)
Additional files

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Sperber K
Hom C
Chao CP
Shapiro D
Ash J

on PubMed

Sperber K
Hom C
Chao CP
Shapiro D
Ash J
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Review

Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases

Kirk Sperber¹ , Christine Hom² , Chun Peng Chao² , Deborah Shapiro¹ and Julia Ash¹

¹Division of Allergy, Immunology, and Rheumatology, Department of Medicine, New York Medical College, Munger Pavilion, Valhalla, NY 10595, USA

²Division of Rheumatology, Department of Pediatrics, New York Medical College, Munger Pavilion, Valhalla, NY 10595, USA

author email corresponding author email

Pediatric Rheumatology 2009, 7:9doi:10.1186/1546-0096-7-9


Published:	13 May 2009

Abstract

Objective

The purpose of this study is to compare the incidence of congenital defects, spontaneous abortions, number of live births, fetal death and pre-maturity in women with autoimmune diseases taking HCQ during pregnancy.

Methods

The authors searched MEDLINE, Cochrane data base, Ovid-Currents Clinical Medicine, Ovid-Embase:Drugs and Pharmacology, EBSCO, Web of Science, and SCOPUS using the search terms HCQ and/or pregnancy. We attempted to identify all clinical trials from 1980 to 2007 regardless of language or publication status. We also searched Cochrane Central Library and http://www.Clinical trials.gov webcite for clinical trials of HCQ and pregnancy. Data were extracted onto standardized forms and were confirmed.

Results

The odds ratio (OR) of congenital defects in live births of women taking HCQ during pregnancy was 0.66, 95% confidence intervals (CI) 0.25, 1.75. The OR of a live birth for women taking HCQ during pregnancy was 1.05 (95% CI 0.58, 1.93). The OR of spontaneous abortion in women taking HCQ during pregnancy was 0.92 (95% CI 0.49, 1.72). The OR of fetal deaths in women taking HCQ during pregnancy was 0.97 (95% CI 0.14, 6.54). The OR of pre-mature birth defined as birth before 37 weeks in women taking HCQ during pregnancy was 1.10 (95% CI 0.75, 1.61).

Conclusion

HCQ is not associated with any increased risk of congenital defects, spontaneous abortions, fetal death, pre-maturity and decreased numbers of live births in patients with auto-immune diseases.